Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707293 | 1.00 | CA1 (0.57) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL4393943 | 1.00 | CA1 (0.57) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL7745206 | 1.00 | CA1 (0.57) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3446599 | 1.00 | CA1 (0.57) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL741043 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL20027586 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL19618687 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL10724727 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL10724721 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5564464 | 0.86 | CA1 (0.55) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3228616-B1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2019-10-16 | — | — | EP | disclosed |
| US-10005762-B2 | Pyridine derivatives | ASTELLAS PHARMA INC. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2017-12-21 | — | — | US | disclosed |
| EP-3228616-A1 | PYRIDINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-5135914-A | Controlling hypertension, hyperaldosteronism, and congestive heart failure | WARNER-LAMBERT COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| US-4548926-A | RENIN INHIBITOR | SANKYO COMPANY LIMITED (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0128762-A2 | New hypotensive peptides, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1984-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005762-B2 | Pyridine derivatives | LAP3, PREP, DNPEP | CA1 273/4885CA2 206/4885CA7 750/4885 |
| US-20170362209-A1 | PYRIDINE DERIVATIVES | LAP3, PREP, DNPEP | CA1 273/4885CA2 206/4885CA7 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.